Literature DB >> 30380143

Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma.

Georgios Gemenetzis1, Vincent P Groot1, Alex B Blair1, Ding Ding1, Sameer S Thakker1, Elliot K Fishman2, John L Cameron1, Martin A Makary1, Matthew J Weiss1, Christopher L Wolfgang1, Jin He1.   

Abstract

BACKGROUND: The incidence of occult metastatic disease (OMD) in pancreatic ductal adenocarcinoma (PDAC) and associated risk factors are largely unknown.
METHODS: We identified all patients with PDAC, who had an aborted oncologic operation due to OMD within a 10-year period. The cases were matched to a cohort of resected PDAC patients on a 1:3 ratio, based on age and sex, for comparison of preoperative clinical characteristics and potential risk factors for OMD.
RESULTS: In the studied period, 117 patients with OMD were identified in 1423 pancreatectomies performed for PDAC (8%). Liver metastases were the most common finding (79%) followed by peritoneal implants (16%). When compared with non-OMD cases, patients with OMD presented more often with abdominal pain (P < 0.001), and higher preoperative carbohydrate antigen 19-9 (CA 19-9) values ( P = 0.007). Additionally, indeterminate liver lesions on preoperative computed tomography (CT) were identified in 40% of OMD versus 17% of non-OMD patients ( P < 0.001). Multivariable analysis distinguished four independent predictors for OMD: indeterminate lesions on preoperative CT, tumor size > 30 mm, abdominal pain, and preoperative CA 19-9 > 192 U/mL.
CONCLUSIONS: Occurrence of OMD in PDAC accounts for 8% of cases. Preoperative CA 19-9 > 192 U/mL, primary tumor size > 30 mm, and identification of indeterminate lesions in preoperative CT may indicate the need for diagnostic laparoscopy.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  diagnostic laparoscopy; indeterminate lesions; metastases; occult; pancreatic cancer

Mesh:

Year:  2018        PMID: 30380143     DOI: 10.1002/jso.25288

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  8 in total

Review 1.  Indications to total pancreatectomy for positive neck margin after partial pancreatectomy: a review of a slippery ground.

Authors:  Stefano Crippa; Giulio Belfiori; Domenico Tamburrino; Stefano Partelli; Massimo Falconi
Journal:  Updates Surg       Date:  2021-07-31

2.  Long-Term Survivors after Upfront Resection for Pancreatic Ductal Adenocarcinoma: An Actual 5-Year Analysis of Disease-Specific and Post-Recurrence Survival.

Authors:  Giulio Belfiori; Stefano Crippa; Aleotti Francesca; Michele Pagnanelli; Domenico Tamburrino; Giulia Gasparini; Stefano Partelli; Valentina Andreasi; Corrado Rubini; Giuseppe Zamboni; Massimo Falconi
Journal:  Ann Surg Oncol       Date:  2021-07-13       Impact factor: 5.344

Review 3.  A NSQIP-based randomized clinical trial evaluating choice of prophylactic antibiotics for pancreaticoduodenectomy.

Authors:  Brian C Brajcich; Clifford Y Ko; Jason B Liu; Ryan J Ellis; Michael I D Angelica
Journal:  J Surg Oncol       Date:  2021-05       Impact factor: 3.454

4.  A nomogram of preoperative predictors for occult metastasis in patients with PDAC during laparoscopic exploration.

Authors:  Jiachen Ge; Lei Li; Zhaolai Ma; Bin Jiang; Chunhui Yuan; Hangyan Wang; Ying Peng; Dianrong Xiu
Journal:  Gland Surg       Date:  2021-01

5.  Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma.

Authors:  Lei Zheng; Ding Ding; Barish H Edil; Carol Judkins; Jennifer N Durham; Dwayne L Thomas; Katherine M Bever; Guanglan Mo; Sara E Solt; Jessica A Hoare; Raka Bhattacharya; Qingfeng Zhu; Arsen Osipov; Beth Onner; Katrina A Purtell; Hongyan Cai; Rose Parkinson; Amy Hacker-Prietz; Joseph M Herman; Dung T Le; Nilofer S Azad; Ana M C De Jesus-Acosta; Alex B Blair; Victoria Kim; Kevin C Soares; Lindsey Manos; John L Cameron; Martin A Makary; Matthew J Weiss; Richard D Schulick; Jin He; Christopher L Wolfgang; Elizabeth D Thompson; Robert A Anders; Elizabeth Sugar; Elizabeth M Jaffee; Daniel A Laheru
Journal:  Clin Cancer Res       Date:  2020-12-04       Impact factor: 13.801

6.  Can preoperative liver MRI with gadoxetic acid help reduce open-close laparotomies for curative intent pancreatic cancer surgery?

Authors:  Kartik S Jhaveri; Ali Babaei Jandaghi; Seng Thipphavong; Osvaldo Espin-Garcia; Anna Dodd; Shawn Hutchinson; Trevor W Reichman; Carol-Anne Moulton; Ian D McGilvary; Steven Gallinger
Journal:  Cancer Imaging       Date:  2021-06-30       Impact factor: 3.909

7.  Performance of Multiparametric Functional Imaging and Texture Analysis in Predicting Synchronous Metastatic Disease in Pancreatic Ductal Adenocarcinoma Patients by Hybrid PET/MR: Initial Experience.

Authors:  Jing Gao; Xinyun Huang; Hongping Meng; Miao Zhang; Xiaozhe Zhang; Xiaozhu Lin; Biao Li
Journal:  Front Oncol       Date:  2020-02-25       Impact factor: 6.244

Review 8.  The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy.

Authors:  Daniel R Principe; Patrick W Underwood; Murray Korc; Jose G Trevino; Hidayatullah G Munshi; Ajay Rana
Journal:  Front Oncol       Date:  2021-07-15       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.